From "up to date": Patients with severe disease

From "up to date":

Patients with severe disease who are receiving supplemental oxygen – For patients on supplemental oxygen (including those who are on high-flow oxygen and noninvasive ventilation), we suggest low-dose dexamethasone. Trial data suggest that dexamethasone improves mortality in patients who are on noninvasive oxygen supplementation; it is uncertain if there are particular patients in this relatively heterogeneous group who would benefit more than others.

For patients who are on low-flow supplemental oxygen only, we also suggest remdesivir. Subgroup analysis of trial data suggests that remdesivir improves mortality in patients who are on low-flow supplemental oxygen, but clinical benefit is less certain in patients who need higher levels of noninvasive support (eg, high-flow oxygenation and noninvasive ventilation). We also suggest remdesivir in patients with higher levels of noninvasive support, but prioritize it for patients on low-flow supplemental oxygen.

Of course I am not sure if this applies to POTUS, unless I had the opportunity to see his chart.